ALK inhibitor

From Wikipedia, the free encyclopedia
Jump to: navigation, search

ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[1]


About 4-7% of non-small cell lung carcinomas (NSCLC) have EML4-ALK translocations.[2]

Approved inhibitors[edit]

Clinical trials[edit]

Additional ALK inhibitors currently (or soon to be) undergoing clinical trials include:

Updates for several of these will be available at the start of June at ASCO 2014.



NPM-ALK is a different variation/fusion of ALK that drives anaplastic large-cell lymphomas (ALCLs) and is the target of other ALK inhibitors.[6] [7]


External links[edit]